Skip to content
Peptigraph home
Shop Peptides50% off*

How Sermorelin Works: Mechanism and Pharmacology

How Sermorelin works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingGHRH analogUpdated
Class
GHRH analog
FDA status
Compounded by prescription
Routes studied
subcutaneous; not stated
Half-life
[pending]
by route, with source

How long it acts

No published half-life found for Sermorelin (PubMed search, 11 Oct 2026)

Full detail, including drug-testing windows, is on the Sermorelin half-life page.

What sermorelin is and what it targets

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone and the shortest synthetic peptide with full GHRH activity.[5]

Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary.[5]

What happens in people

In old men, twice-daily GHRH injections evoked dose-related increases in 24-hour GH release and IGF-I, significant at the high dose.[6]

In older men given nightly injections, nocturnal GH release rose but IGF-I, IGFBP-3 and GH binding protein did not.[7]

In growth-hormone-deficient children, daily subcutaneous GHRH raised mean height velocity from 4.1 to 8.0 cm/yr at 6 months.[8]

Timing, limits and what is unknown

Older men took GHRH twice daily for 14 days, with a 14-day break between the low-dose and high-dose courses.[6]

The review notes that the effect of long-term sermorelin on final adult height was yet to be determined.[5]

In children given twice-daily GHRH, anti-GHRH antibodies developed in 14 patients without apparent effects on growth or GH responses.[9]

The pharmacokinetics PubMed query run on 2026-10-02 for (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) found 2 results.

Calculated from query (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]); date 2026-10-02; result count 2. Formula: count reported by the search record in the evidence file

Related peptides

Sermorelin vs TesamorelinGHRH analogSermorelin vs IpamorelinGHRP (ghrelin receptor agonist)Sermorelin vs CJC-1295GHRH analogSermorelin vs CJC-1295 + IpamorelinGHRH + GHRP blend

Common questions

How long does Sermorelin act in the body?

We found no published half-life for Sermorelin (PubMed search, 11 Oct 2026), so how long it acts is unknown.

How does sermorelin work?

It mimics growth hormone-releasing hormone, prompting the pituitary to release growth hormone.[5]

Does sermorelin really work?

In growth-hormone-deficient children, 74% had a good response at 6 months in one open-label study; in healthy older men the studies measured hormone levels rather than clinical benefit.[8]

How long for sermorelin to work?

In children the height-velocity gain was reported at 6 months, and in older men hormone changes were measured after a short course.[8]

More on Sermorelin

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.BenefitsClaimed benefits next to what published studies measured.

Sources

  1. 1PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  5. 5Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999PMID 18031173Accessed 2 Oct 2026
  6. 6Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  7. 7Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  8. 8Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  9. 9Treatment of growth-hormone deficiency with growth-hormone-releasing hormone.Lancet (London, England) · 1987PMID 2879138Accessed 11 Oct 2026

Found an error? Report a correction.